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Review
Life-long diseases need life-long treatment: 
long-term safety of ciclosporin in canine atopic 
dermatitis
Tim Nuttall, Douglas Reece, Elizabeth Roberts
Ciclosporin (Atopica; Novartis Animal Health) has been licensed for canine atopic dermatitis (AD) 
since 2002. Adverse events (AEs) have been reported in 55 per cent of 759 dogs in 15 clinical 
trials, but are rare in pharmacovigilance data (71.81 AEs/million capsules sold). Gastrointestinal 
reactions were most common, but were mild and rarely required intervention. Other AEs were 
rare (≤1 per cent in clinical trials; <10/million capsules sold). Hirsutism, gingival hyperplasia 
and hyperplastic dermatitis were rarely significant and resolved on dose reduction. Ciclosporin 
decreases staphylococcal and Malassezia infections in AD, and at the recommended dose is not 
a risk factor for other infections, neoplasia, renal failure or hypertension. The impact on glucose 
and calcium metabolism is not clinically significant for normal dogs. Concomitant treatment 
with most drugs is safe. Effects on cytochrome P450 and MDR1 P-glycoprotein activity may 
elevate plasma ciclosporin concentrations, but short-term changes are not clinically significant. 
Monitoring of complete blood counts, urinalysis or ciclosporin levels is not justified except with 
higher than recommended doses and/or long-term concurrent immunosuppressive drugs. 
Ciclosporin is not a contraindication for killed (including rabies) vaccines, but the licensed 
recommendation is that live vaccination is avoided during treatment. In conclusion, ciclosporin 
has a positive risk-benefit profile for the long-term management of canine AD. 
CiClosporin (ciclosporine, cyclosporine, cyclosporin A or CsA) is 
a cyclic oligopeptide macrolide that inhibits cytoplasmic calcineurin 
phosphatase (steffan and others 2006). Ciclosporin blocks induction 
of genes for a variety of cytokines and cytokine receptors, resulting 
in immunomodulating activity. its effects on cytokines involved in 
the activation, proliferation and survival of cells important in cuta-
neous immunity and allergic reactions, including langerhans’ cells, 
lymphocytes, mast cells and eosinophils, led to interest in using it 
to manage canine atopic dermatitis (AD). A small open study show-
ing efficacy in reducing clinical lesions and pruritus was published 
in 2001 (Fontaine and olivry 2001). since then there have been 
numerous other studies from the UsA, Europe, Japan and Australia. 
Ciclosporin was licensed for the management of canine AD in 2002 
as Atopica (novartis Animal Health) and is now approved and avail-
able in 23 countries worldwide. in 2006, a meta-analysis of 10 studies, 
including 799 dogs, concluded that oral ciclosporin was as effective 
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as systemic glucocorticoids (steffan and others 2006). other meta-
analyses and systematic reviews have also confirmed that ciclosporin 
is highly effective in the treatment of canine AD (olivry and Mueller 
2003, olivry and others 2010a, olivry and Bizikova 2013), and the 
2010 international Task Force for Canine Atopic Dermatitis (now the 
international Committee for Allergic Diseases in Animals [iCADA]) 
practice guidelines for the treatment of canine AD specifically recom-
mended ciclosporin in the management of chronic AD (olivry and 
others 2010b). 
Canine AD is a disease of young animals, with the peak age of 
onset between six months and three years (Favrot and others 2010). it 
is a chronic relapsing condition and most dogs will require ongoing, 
usually life-long, therapy. it is therefore important to understand the 
long-term safety of therapeutic interventions to balance efficacy and 
adverse effects in order to maintain a good quality of life. safety data 
for registration usually only includes clinical trial data from relatively 
small numbers of dogs treated for weeks to months. Therefore, the 
monitoring of the safety and efficacy of marketed medicines through 
pharmacovigilance (pV) is an essential and efficacious tool to assess 
a drug’s safety and efficacy profile. Adverse effects that occur at low 
rates, have a breed predilection or drug:drug interactions may not be 
evident during clinical trial investigation. For pV purposes, adverse 
effects are any side effect, injury, toxicity or sensitivity reaction asso-
ciated with use of an animal drug, whether or not considered to be 
drug related and whether or not the drug was used in accordance with 
the approved labelling, and can include product reports of failure to 
perform as expected. 
in the 10 years or so that Atopica has been available an estimated 
142 million doses of ciclosporin have been sold (roberts and others 
2012a). This provides a wealth of experience and data on the safety 
of ciclosporin in dogs with AD. The aim of this review is to ana-
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lyse published papers and pV data to report the prevalence of adverse 
effects associated with ciclosporin treatment. This data will be useful 
to clinicians when discussing treatment options with the owners of 
atopic dogs. 
Analysis of adverse effects associated with 
ciclosporin treatment
A wide variety of adverse effects have been associated with ciclo-
sporin treatment. This review discusses these effects grouped by body 
system and/or tissue in more detail, reviewing the strength of associa-
tion with ciclosporin and the relative risk. This review is complicated 
by the variety of different reports that include pV data, experimental 
studies, single case studies, clinical trials, meta-analyses and systematic 
reviews. in particular, it is difficult to determine the significance of 
adverse effects where there is no control group to permit case-control 
analysis and calculation of risk. This confounding by indication cre-
ates a bias in the pV dataset as the indication for treatment (atopic 
dermatitis) may be related to a higher prevalence of specific adverse 
events in a ciclosporin treatment group than one would see in a con-
trol group or the general population. Data from single case reports 
may be limited, as the report may be spontaneous, confounded by 
the presence of unrelated disease or concomitant therapy such that 
the association is speculative. A plausible association with ciclosporin 
can be made where there is a valid link between drug exposure and 
an adverse drug reaction (ADr), such as when an ADr occurs early 
in treatment and resolves with reduction of the dose or cessation of 
therapy. However, it can be difficult to confirm causality as dogs may 
have concurrent treatment or conditions that could also explain the 
observed clinical signs. 
Establishing a valid link between drug exposure and an ADr is 
based on detailed medical and drug history, but there are no specific 
diagnostic criteria. several methods (eg, naranjo scale, ABon system, 
rUCAM method, modified Kramer algorithm and others) have been 
used to determine the causality association or assessment of an ADr. 
Unfortunately, very few published veterinary reports use these scores 
for evaluation.
it is also important to note that the analysis of adverse events and 
development of a risk-benefit profile for a product to treat a non-life 
threatening condition would be considered acceptable for a high prev-
alence of mild adverse events, but would be unacceptable for a low 
prevalence of severe adverse effects. 
Adverse effects associated with ciclosporin 
treatment for canine atopic dermatitis
This article has analysed and reviewed data from peer-reviewed stud-
ies and published clinical trials reporting the outcomes of treatment 
of canine AD at standard doses (ie, a starting dose of approximately 5 
mg/kg once daily, tapered to clinical effect) of ultramicronised emulsi-
fied ciclosporin administered orally (Atopica). Unpublished studies, 
experimental studies in healthy dogs, studies in other species, and off-
label use in other conditions, at other doses and/or combined with 
other medication were not included in the analysis but have been 
quoted where appropriate when discussing the likely significance of 
certain adverse effects. The review of pV data included off-label use 
in other conditions, at other doses and/or treatment combined with 
other medication. 
This resulted in a meta-analysis of data from 15 studies includ-
ing 759 dogs. All but one study used oral ultramicronised emulsified 
ciclosporin as Atopica; the exception used a generic ultramicronised 
emulsified ciclosporin (Equoral; Teva pharmaceuticals) (Kovalik and 
others 2011a). The findings are summarised in Table 1, which reports 
findings of all dogs that had at least one adverse event reported. This is 
an approximation of the true figures, as it was not always clear wheth-
er some dogs had more than one adverse event (and therefore were 
counted more than once) and some dogs had multiple episodes of the 
same adverse event (which only counted once). Finally, adverse events 
that were clearly unrelated to treatment were disregarded (eg, road traf-
fic accidents, cruciate injuries, foreign bodies, etc). pharmacovigilance 
data (roberts and others 2012a) was reviewed in light of the meta-
analysis for consistency and completeness (Table 2). 
At least one adverse event was reported in 420 of 759 treated dogs 
(55 per cent, with a range of 0 to 88 per cent among the individual 
studies). However, the majority of these were mild and self-limiting 
requiring cessation of treatment in only 4 per cent of cases (range 0 to 
17 per cent). The most frequent adverse events were gastrointestinal 
(51 per cent; range 0 to 60 per cent), which is consistent with the pV 
data, and other problems were seen in no more than 1 per cent of 
treated dogs. There was considerable variation between studies, which 
probably reflects the number of dogs and duration of treatment. There 
was also some variation in terminology of recording the adverse 
events (eg, between different gastrointestinal and urinary tract clini-
cal signs). in addition, there may have been differences in how each 
study asked for and recorded possible adverse events. non-clinically 
significant changes in haematology, biochemistry and other param-
eters were not recorded as individual adverse events but mean values 
and changes, where available, are discussed later. 
Gastrointestinal adverse effects
Gastrointestinal upsets are the most common adverse effects associ-
ated with ciclosporin. They occurred in 46 per cent of the 759 dogs 
included in Table 1, and were the only ADrs consistently reported in 
most studies. Table 2 shows that the top two clinical signs reported 
to pV also included signs of gastrointestinal upset (eg, vomiting and 
diarrhoea). in another meta-analysis of 672 atopic dogs treated with 
ciclosporin, gastrointestinal problems were recorded in 306 (45 per 
cent) of dogs, whereas other adverse effects were seen in less than 2.1 
per cent (steffan and others 2006). However, these figures could have 
overestimated the prevalence of gastrointestinal upsets as individual 
dogs were reported to have had multiple events. Vomiting, reported 
in 25 to 31 per cent of dogs, was three to four times more likely in 
ciclosporin-treated dogs compared to controls. soft stools, diarrhoea 
and/or other problems affected 18 to 20 per cent of the ciclosporin-
treated dogs, roughly twice the proportion of the control groups (Table 
1) (steffan and others 2006). The incidence appears to be dose-related, 
and may involve reversible microvilli damage caused by excipients in 
the oral microemulsified formulation (nerurkar and others 1996).
Most of the gastrointestinal upsets appeared to be mild, with 
repeated or prolonged episodes of vomiting or other problems rarely 
reported (steffan and others 2006). Two studies specifically reported 
the number of gastrointestinal disturbances per dog (olivry and others 
2002a, steffan and others 2005). of the dogs with at least one gas-
trointestinal adverse effect, 53 per cent to 73 per cent vomited one to 
three times over three months, with most episodes recorded in the first 
month of treatment. only 10 per cent of dogs had multiple sporadic 
episodes of vomiting and vomiting was considered severe in only 1 
per cent of cases (steffan and others 2005). The incidence of soft stools 
or diarrhoea was similar to that of vomiting (olivry and others 2002a, 
steffan and others 2005). in the largest study, diarrhoea was seen in 
53 of 266 dogs (20 per cent), and was associated with vomiting in 10 
dogs. Most cases were seen in the first month of treatment (steffan 
and others 2005), resolved without treatment in all but two dogs, and 
were considered severe in only one dog. single episodes were seen in 
43 per cent of dogs, while multiple episodes were reported in 28 per 
cent. Most episodes were self-limiting, with clinical signs for seven 
days or more reported in only 13 per cent of dogs. loss of appetite was 
only seen in 2 per cent of treated dogs (Table 1) (steffan and others 
2006), where it was usually associated with vomiting or diarrhoea 
(steffan and others 2005). Weight loss has been seen in <1 per cent 
of dogs (steffan and others 2006); in one study only one of 266 dogs 
experienced weight loss and this was associated with an unrelated 
hepatopathy (steffan and others 2005). Unacceptable gastrointestinal 
problems requiring cessation of treatment were rare; in one study this 
was reported in only two of 266 dogs (steffan and others 2005). 
Conclusions and recommendations
Gastrointestinal reactions are the most common adverse events report-
ed in dogs treated with ciclosporin. These are usually mild, do not 
require treatment, and rarely require discontinuation of ciclosporin. 
suggestions from the literature to reduce the incidence of vomit-
ing and/or diarrhoea are to start treatment with a low dose (1 to 2 
mg/kg every 24 hours) gradually increasing to the therapeutic dose 
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(5 mg/kg every 24 hours) or reducing the dose regime (eg, from daily 
to every other day or twice weekly). other options include chilling 
or freezing the ciclosporin for 30 to 60 minutes before administra-
tion (palmeiro 2013). Administering ciclosporin in food may also help 
(palmeiro 2013), although adverse effects were equally frequent with 
and without food in one small study (Thelen and others 2006). if nec-
essary, vomiting may be managed with antiemetics (eg, maropitant 
or metoclopramide) (palmeiro 2013) or gastric protectants (eg, sucral-
fate, cimetidine or ranitidine). sucralfate should be given at least one 
hour before ciclosporin to avoid reducing absorption and bioavailabil-
ity. High-fibre supplements (such as canned pumpkin) and probiotics 
may help ameliorate soft stools or diarrhoea (palmeiro 2013). Zinc-
carnosine and vitamin E supplementation (Gastri-Calm; Teva Animal 
Health) has failed to alleviate gastrointestinal side effects associated 
with ciclosporin therapy (Wilson and others 2011).
Papillomatous, psoriasiform and/or  
verrucose dermatitis
papillomatous skin lesions or other ‘skin hyperplasia’ were observed 
in five of 672 (0.7 per cent) dogs in one meta-analysis (steffan and oth-
ers 2006). proliferative skin lesions were seen in 1 per cent of the 759 
dogs in Table 1. Three cases of psoriasiform lichenoid dermatitis were 
also described (Werner 2003). These responded to withdrawal of ciclo-
sporin and treatment with antibiotics. papillomatosis and verrucose 
dermatitis have also been reported to resolve following reduction of 
the dose or withdrawal of treatment (seibel and others 1989a, olivry 
and others 2002b, Favrot and others 2005). The incidence and sever-
ity appears to be dose related, with generalised papillomatosis seen in 
five of eight dogs given 45 mg/kg daily for 12 months (Donatsch and 
ryffel 1986). 
These lesions are rarely associated with papillomavirus infection 
(Donatsch and ryffel 1986, seibel and others 1989a, Favrot and oth-
ers 2005). in one study, seven of nine dogs with lesions consistent 
with psoriasiform lichenoid dermatosis were negative for papilloma-
virus by immunohistochemistry and pCr (Favrot and others 2005). 
Histopathological evidence of staphylococci supports the suggestion 
that these lesions, at least in part, represent a reaction to bacterial colo-
nisation and/or infection (Werner 2003). The other two dogs in the 
study had verrucose lesions with histopathological evidence of viral 
infection, including koilocytes and nuclear viral inclusions. These 
lesions were positive for papillomavirus and pCr amplified DnA 
characteristic of canine oral papillomavirus and canine papillomavirus 
type 2. All the lesions resolved on withdrawal of ciclosporin without 
further treatment. one case of oral viral papilloma was reported in an 
atopic dog (radowicz and power 2005); the papilloma was success-
fully excised and did not recur despite ongoing ciclosporin treatment. 
Conclusions and recommendations
Various hyperplastic lesions of the skin have been associated with 
ciclosporin treatment in dogs. These are uncommon and rarely of any 
clinical significance; this assessment is also consistent with reported 
pV data. Most resolve on dose reduction or cessation of therapy with-
out the need for further treatment. 
Gingival hyperplasia
The prevalence of gingival hyperplasia was 1 per cent identified in 
this review (Table 1), 1.7 per cent in one unpublished meta-analysis 
of 609 dogs (C. Favrot, unpublished observations) and 1.3 per cent in 
another analysis of 672 dogs (steffan and others 2006). in most cases 
the gingival hyperplasia was mild and did not warrant cessation of 
therapy. The hyperplasia was probably associated with transform-
ing growth factor beta (TGFb)-mediated proliferation of the extra-
cellular matrix (stabellini and others 2002). The effect appears to 
be dose-dependent although there was individual variation, which 
may reflect variable metabolism and pharmacodynamics (seibel and 
others 1989b). Gingival hyperplasia was particularly severe and fre-
quent in a group of dogs treated with 45 mg/kg daily for 12 months 
(Donatsch and ryffel 1986). in an experimental transplantation 
study, three of four dogs treated with adjusted doses of ciclosporin 
to maintain whole blood trough concentrations of 400 to 700 ng/
ml started to develop moderate to severe gingival hyperplasia by 20 
weeks. However, these dogs were also treated with azathioprine 
and, for the first three months, prednisolone to prevent graft rejec-
tion (nam and others 2008).
Table 1: Analysis of 15 trials including 759 dogs treated with ciclosporin for canine atopic dermatitis
Total Fontaine 
and Olivry 
2001
Iwasaki 
and others 
2002
Olivry and 
others 
2002a
Olivry 
and 
others
2002b
Steffan 
and others
2003
Olivry 
and 
others 
2003
Burton 
and 
others 
2004
Bensignor 
and 
Guaguère 
2004
Steffan 
and 
others 
2005
Thelen 
and 
others 
2006
Carlotti 
and 
others 
2009
Nuttall 
and 
others 
2012
Kovalik 
and others 
2011a*
Kovalik 
and 
others 
2012
Dip and 
others 
2013
Number (%) of dogs 759 14 92 61 15 117 30 41 15 266 25 8 21 13 16 25
Vomiting 26% 2 (14) 10 (11) 23 (38) 1 (7) 43 (37) 6 (20) 4 (10) 5 (33) 82 (31) 0 0 6 (29) 3 (23) 2 (13) 10 (40)
Soft stools/diarrhoea 15% 0 13 (14) 21 (34) 3 (20) 6 (5) 0 4 (10) 0 53 (20) 0 0 2 (10) 2 (15) 5 (31) 5 (20)
Miscellaneous 3% 0 0 0 1 (7) 10 (9) 1 (3) 0 0 0 10 (40) 0 0 0 0 2 (8)
Loss of appetite 2% 0 1 (1) 0 0 5 (4) 0 0 0 8 (3) 0 0 1 (5) 0 0 0
Nodules/cyst 1% 0 0 0 0 7 (6) 0 0 0 3 (1) 0 0 0 0 0 0
Urinary tract infection 1% 0 0 0 0 0 0 0 0 10 (4) 0 0 0 0 0 0
Gingival hyperplasia 1% 0 0 0 0 3 (3) 0 0 0 6 (2) 0 0 0 0 0 0
Lethargy/lameness 1% 0 0 0 1 (7) 0 0 0 1 (7) 6 (2) 0 0 0 0 0 1 (4)
Reproductive 1% 0 0 0 0 7 (6) 0 0 0 0 0 0 0 0 0 0
Papillomatosis 1% 0 0 0 1 (7) 0 1 (3) 0 0 4 (2) 0 0 0 0 0 1 (4)
Lymphadenopathy 0.8% 0 0 0 0 0 0 0 0 6 (2) 0 0 0 0 0 0
Neurological 0.8% 0 0 0 0 0 0 0 0 4 (2) 1 (4) 0 0 0 0 1 (4)
Other urine 
abnormalities
0.3% 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 (8)
Urticaria/ 
angio-oedema
0.3% 0 0 0 1 (7) 0 1 (3) 0 0 0 0 0 0 0 0 0
ADR requiring 
cessation of therapy
5% 0 5 (5) 0 2 (13) 10 (9) 5 (17) 0 0 11 (4) 3 (12) 0 0 0 0 0
Total 59.2% 14% 31% 72% 68% 79% 46% 20% 40% 73% 56% 0% 44% 38% 44% 88%
* All the trials used 5 mg/kg ciclosporin as Atopica (Novartis Animal Health) except Kovalik and others 2011a, which used 5 mg/kg ciclosporin as Equoral oral solution (Teva 
Pharmaceuticals)
ADR Adverse drug reaction
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Conclusions and recommendations
Gingival hyperplasia is rare with standard doses of ciclosporin used to 
treat canine AD. in most cases the gingival hyperplasia is mild and of 
little clinical significance, but in rare cases it can be more severe with 
significant tooth occlusion and gingivitis. The gingival hyperplasia 
responds favourably to reduction of the dose or cessation of treatment. 
Mild cases may require dental hygiene to help prevent gingivitis. 
Azithromycin seems to be of additional benefit in humans 
(ramalho and others 2007). in one study of 36 dogs with ciclosporin-
associated gingival hyperplasia, brushing with an 8.5 per cent azithro-
mycin toothpaste or systemic azithromycin (10 mg/kg) every 24 hours 
significantly decreased the gingival sulcus depth compared to placebo 
groups, but there was no change in tooth length or subjective global 
scores and only one dog in the systemic azithromycin group had com-
plete remission (rosenberg and others 2013). 
Hirsutism or hypertrichosis
Hirsutism or hypertrichosis are rarely reported as adverse effects; less 
than 1 per cent in one unpublished meta-analysis of 609 dogs (C. 
Favrot, unpublished observations), with no reports in many studies 
(Table 1) (steffan and others 2006). nevertheless, hirsutism and/or 
hypertrichosis is frequently reported in dogs treated with ciclosporin 
(seibel and others 1989a, robson and Burton 2003). initially, some 
animals experience a heavy shedding approximately four to six weeks 
after initiation of ciclosporin therapy. Ciclosporin induces the hair fol-
licle to stay in a prolonged anagen (growth) phase and induces catagen 
(transitional) and telogen (resting) follicles to enter the anagen phase. 
This causes a somewhat synchronised telogen phase resulting in an 
increase in shedding. The hair follicles then begin to produce new 
growth, probably associated with ciclosporin-induced inhibition of 
the calcineurin-nFAT1 pathway in follicular keratinocytes resulting 
in the growth of a thicker and glossier haircoat (Gafter-Gvili and oth-
ers 2003).
Conclusions and recommendations
Hirsutism or hypertrichosis is a benign consequence of ciclosporin 
therapy. it is rarely clinically significant, but individual dogs may need 
more frequent grooming to prevent matting of the coat, particularly 
in interdigital areas.
Infections
long-term use of immunomodulating agents could increase the risk 
of infection with bacterial, fungal, viral, protozoal or other organisms 
such as Demodex species. Ciclosporin shows dose and time-dependent 
immunosuppressive activity, with suppression of interleukin (il)-2, 
il-4, interferon (iFn)-g, CD25 and CD95 expression by activated T 
cells (Fellman and others 2011), although in healthy dogs only the 
effects on il-2 and iFn-g were significant (Archer and others 2011). 
However, one study using 5 mg/kg generic ciclosporin (Equoral) 
daily for 42 days in 13 dogs did not show any significant effects on 
metabolic or functional activity of phagocytic cells compared to 1 mg/
kg prednisolone (Kovalik and others 2011a). A further in vitro study 
using the canine keratinocyte cell line CpEK showed that ciclosporin 
increased il-8 and tumour necrosis factor-a mrnA expression in 
response to toll-like receptor 2 ligands (Hendricks and others 2012), 
suggesting that ciclosporin may actually enhance innate immunity 
in the skin. 
Staphylococcal and Malassezia skin and ear infections
staphylococcal and Malassezia skin and ear infections are common 
in canine AD. However, while these may contribute to on-going 
inflammation, it is thought that colonisation and infection is a conse-
quence of altered skin barrier function and cutaneous immunity inher-
ent with canine AD (nuttall and Halliwell 2001, Bexley and others 
2013). in one study, treatment with ciclosporin significantly decreased 
the prevalence of secondary infections (steffan and others 2003), sug-
gesting that effective control of canine AD reduces the frequency and 
severity of infections. psoriasiform lichenoid dermatosis (see above) 
has been associated with staphylococci, and may be an unusual reac-
tion to bacterial colonisation and/or infection in some dogs on ciclo-
sporin therapy (Werner 2003, Favrot and others 2005). These lesions 
usually resolve on withdrawal of ciclosporin, but some dogs may also 
need antibiotic treatment. 
Urinary tract infections
reports of bacteriuria and lower urinary tract infections seem to be 
rare, reported in just 1.3 per cent of 759 treated dogs (Table 1). in an 
exception to this, one clinical trial recorded bacteria present in at least 
one urine sample from 51 per cent of 89 treated dogs (steffan and 
others 2005). only one dog developed clinical evidence of cystitis, 
although another nine dogs were considered to have asymptomatic 
urinary tract infections. This has not been reported elsewhere, but 
urine samples were not routinely examined in all studies (steffan and 
others 2006). However, 24 per cent of dogs in this study were posi-
tive for bacteriuria at enrolment and the prevalence remained stable 
throughout the trial, with some fluctuations from positive to negative 
and vice versa. it is possible that this high prevalence reflected prior 
therapy with systemic glucocorticoids rather than ciclosporin treat-
ment during the trial. 
in a study following 38 dogs for up to two years of treatment, 
three dogs developed bacteriuria, which was confirmed by culture 
(radowicz and power 2005). A further 18 cultures from random 
samples with normal sediment exams were negative, and none of the 
dogs developed clinical signs consistent with a urinary tract infection. 
A more recent retrospective study reported that 26 of 87 dogs with 
chronic inflammatory skin disease treated with ciclosporin with and 
without glucocorticoids for at least five months had at least one posi-
tive urine culture (peterson and others 2012). This was significantly 
higher than in a non-treated control group, but there were no signifi-
cant differences between the control group and either dogs treated 
with ciclosporin alone or ciclosporin and glucocorticoids. no clinical 
signs of urinary tract infection were noted in any of the dogs. Urine 
culture was more sensitive than sediment examination, and it is there-
fore possible that earlier studies have underestimated the prevalence 
of bacteriuria. However, it is difficult to differentiate the effect of the 
glucocorticoids from that of the ciclosporin in this study. 
Other infections
other bacterial infections (including gingivitis, pyometra and respira-
tory tract infections) have been seen in dogs treated with ciclosporin, 
but these are uncommon and no more frequent than in the general 
canine population (steffan and others 2006). Clostridial enteritis was 
diagnosed in one of 266 dogs in one trial (steffan and others 2005), 
while a further dog developed a non-specific metronidazole responsive 
diarrhoea. Disseminated nocardiosis was seen in one dog treated with 
ciclosporin and ketoconazole for AD (paul and others 2010).
other infections are rare. one dog on a renal transplant dose of 
ciclosporin developed toxoplasmosis, although the dog was also treat-
ed with prednisolone and azathioprine to prevent transplant rejec-
tion (Bernsteen and others 1999). This case was associated with a 
seropositive donor and possible reactivation of latent Toxoplasma cysts 
in the renal allograft. There is a single case report of reactivation of 
leishmaniasis in a four-year-old chow chow dog treated with 5 mg/
kg ciclosporin daily for presumed AD. The dog had been successfully 
treated a year earlier with meglumine antimonate and allopurinol, 
and responded to the withdrawal of ciclosporin, and additional treat-
ment with meglumine antimonate and allopurinol (navarro and 
others 2008). Another study reported that treatment with 3.5 mg/
kg ciclosporin and glucantime for six days in dogs with leishmaniasis 
was well tolerated with no evidence of clinical relapse (pugliese and 
others 1997). 
Viral, fungal and Neospora infections were also seen in dogs treated 
with ciclosporin, prednisolone or methylprednisolone, and azathio-
prine or chlorambucil to manage immune-mediated disease. Multiple 
papillomavirus-associated epidermal hamartomas and squamous cell 
carcinomas in situ were seen in a dog following chronic treatment 
with prednisolone and ciclosporin (Callan and others 2005). Despite 
this, concurrent therapy with ciclosporin (5 mg/kg every 24 hours) 
and prednisolone (1 mg/kg every 24 hours for seven days and then 
1 mg/kg every 48 hours for 14 days) did not significantly increase 
the incidence of adverse effects compared to using ciclosporin alone. 
Adverse effects were restricted to those expected from ciclosporin (ie, 
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mild to moderate gastrointestinal upsets) and prednisolone (ie, poly-
phagia, polyuria/polydipsia and other systemic effects); none were 
severe enough to warrant cessation of therapy and no infections were 
noted (Dip and others 2013). 
Conclusions and recommendations
it is likely that effective management of canine AD will reduce the 
frequency of secondary staphylococcal and Malassezia skin and ear 
infections. The presence of such infections is not, therefore, a con-
traindication for treatment with ciclosporin. Topical and/or systemic 
antimicrobial therapy should nevertheless be used to manage infec-
tions in appropriate cases (Beco and others 2013). 
other opportunistic infections are rare. routine urinalysis is not 
generally indicated in dogs undergoing long-term treatment with 
ciclosporin at 5 mg/kg, although further studies are required. As a 
lower urinary tract infection (ie, bacterial cystitis) may (albeit rarely) 
develop into a potentially life-threatening pyelonephritis in an immu-
nosuppressed dog, periodic urine culture may be prudent. likewise, in 
the absence of firm data serological monitoring of leishmaniasis may 
be warranted for dogs that live in endemic areas. Concurrent treat-
ment with prednisolone for the first three weeks of ciclosporin thera-
py does not appear to be a concern. nevertheless, care should be taken 
in dogs treated at higher doses and/or with long-term concurrent treat-
ment with other immunomodulating or immunosuppressive drugs. 
Effects on systemic metabolism and homeostasis
Calcium metabolism
in people, ciclosporin therapy in organ transplant medicine is associ-
ated with osteoporosis, osteomalacia and an increased risk of bone 
fracture (Epstein 1996). This appears to be associated with increased 
plasma parathyroid hormone (pTH) and decreased 1,25-dihydroxyvi-
tamin D (1,25[oH]2D) concentrations. Despite this, there are no pub-
lished descriptions of altered bone density or an increased risk of frac-
tures in atopic dogs. in one study, 16 atopic dogs treated with 4.4-6.0 
mg/kg ciclosporin every 24 hours for six weeks showed no significant 
changes in serum concentrations of plasma total and ionised calcium, 
phosphate, creatinine, 25(oH)D, 1,25(oH)2D, or urinary fractional 
excretion of calcium and phosphate (Kovalik and others 2012). Mean 
plasma pTH concentrations significantly increased following ciclo-
sporin treatment, but the proportion of dogs with plasma pTH lev-
els above the reference range was similar before and after treatment. 
plasma pTH levels increased in 10 of 16 dogs, but decreased or did not 
change in the other six dogs, and levels increased out of the reference 
range in only three dogs. However, the lack of a control group makes 
it difficult to interpret the significance of these findings. 
Glucose metabolism
Diabetes mellitus is rare in dogs treated with ciclosporin. it has been 
associated with West Highland white terriers in Europe (which is 
now listed on the European Medicines Agency summary of product 
Characteristics), but overall appears to be no more frequent than in the 
general canine population (steffan and others 2006). one dog devel-
oped glycosaemia and overt diabetes mellitus three months after com-
pleting four months of treatment at 5 mg/kg daily tapered to every 
other day (steffan and others 2003). pV data supports the observa-
tion that diabetes mellitus is rare; however, it is interesting to note 
that the pV data also shows that treatment with ciclosporin in West 
Highland white terriers in the UK appears to be associated with an 
increased incidence of diabetes mellitus (roberts and others 2012a). 
Ciclosporin can increase peripheral insulin resistance and decrease 
insulin secretion (Wahlstrom and others 1990). These changes are 
reversible and dogs given 20 mg/kg ciclosporin daily remained nor-
moglycaemic (Basadonna and others 1988). However, a study of 16 
dogs with AD showed that treatment with 5 mg/kg ciclosporin once 
daily for six weeks significantly elevated median serum fructosamine 
concentrations compared to baseline (Kovalik and others 2011b). 
plasma glucose levels were significantly increased and serum insulin 
concentrations were significantly lower. peak glucose concentrations 
were significantly increased following glucagon stimulation tests, but 
there was no difference in insulin concentrations. no dogs developed 
overt diabetes mellitus and fructosamine levels remained within the 
normal reference range in all cases. interestingly, diabetic dogs show 
significantly increased total body clearance of ciclosporin compared to 
healthy dogs, possibly associated with a decreased half-life (9.3 hours 
compared to 22.6 hours) (Alkharfy 2009).
Miscellaneous
no consistent abnormalities in haematology or serum biochemistry 
have been associated with ciclosporin therapy in the absence of a con-
current condition (steffan and others 2003, 2006). in one trial using 
3.3 to 6.6 mg/kg, mean haematology and serum biochemistry param-
eters remained within normal limits after eight and 16 weeks of treat-
ment (steffan and others 2005). statistically significant changes were 
seen in a small number of dogs (including increased red cell, white 
cell and lymphocyte counts; and changes in urea, creatinine and total 
protein), but these typically remained within 5 per cent of the baseline 
values. other changes included mild hypercholesteraemia in 2.6 per 
cent of dogs, mild hypocalcaemia in 2.3 per cent, and a 5 to 10 per cent 
reduction in alanine aminotransferase (AlT) and alkaline phosphatase 
(Ap) activity. Even in dogs given 45 mg/kg ciclosporin daily for 12 
months there was no evidence of toxic effects on the liver, kidney, 
bone marrow or other organs (Donatsch and ryffel 1986). Mild anae-
mia and hypoalbuminaemia in two of eight dogs was attributed to 
malnutrition; mild eosinopenia in three of eight dogs was associated 
with stress; and increases in b- and g-globulins were associated with 
pre-existing infection. All the changes appeared to be reversible. in 
addition, reversible increased erythrocyte sedimentation rate, hyper-
proteinaemia, hyperglobulinaemia, hypoalbuminaemia, hypocal-
caemia, hypophosphataemia and hypomagnesaemia have also been 
observed at three and five times the recommended 5 mg/kg dose in 
healthy beagles (novartis Animal Health, internal data). 
Conclusions and recommendations
Ciclosporin treatment in dogs can result in elevated pTH levels, 
decreased insulin secretion and peripheral insulin resistance. However, 
the impact of ciclosporin treatment at the recommended dose on calci-
um and glucose metabolism is minimal, and there is little evidence of 
systemic toxicity. Further action or monitoring is not required in most 
dogs, although periodic monitoring of blood glucose or fructosamine 
concentrations may detect early signs of reduced insulin production 
and insulin-resistance. Care should be taken when treating dogs with 
pre-existing diabetes mellitus or pTH abnormalities. 
Neoplasia
it is possible that ciclosporin may inhibit cytotoxic T cell-mediated 
anti-tumour immune surveillance. in human transplant patients there 
is a two-fold increase in malignancies following ciclosporin (at up 
to 18 mg/kg) (Cockburn 1989). similar findings have been reported 
in cats (schmiedt and others 2009) and there is a single case report 
of lymphoma developing in an 11-year-old German shepherd dog 
Table 2: Top 10 adverse clinical signs associated with ciclosporin 
treatment in dogs reported to pharmacovigilance between 
September 2002 and March 2012
Adverse clinical signs Absolute incidence*
All suspected adverse events 71.81
Vomiting 27.57
Diarrhoea 13.46
Lethargy 9.58
Abnormal test result† 8.59
Pruritus 7.80
Anorexia 6.65
Hyperactivity 3.22
Gingival disorder 2.98
Tachypnoea 2.96
Polydipsia 2.58
* Number of dogs affected/1 million capsules sold
† Includes various clinical pathology values outside of their normal range
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after four weeks treatment with ciclosporin for anal furunculosis 
(Blackwood and others 2004). However, the risk appears to be associ-
ated with the degree of immunosuppression and not ciclosporin spe-
cifically; for example, human transplant patients medicated with aza-
thioprine with or without steroids have a two- to four-fold increased 
risk of malignancy, but there is no increased risk in patients treated 
with ciclosporin at 1.3 to 10 mg/kg daily to manage rheumatoid 
arthritis (Cockburn 1989, van den Borne and others 1998). in addi-
tion, there is evidence that ciclosporin may be protective against some 
forms of colorectal cancer, glioblastoma, bladder tumours and leukae-
mia through activation of p53 (Weischer and others 2007). in contrast, 
however, ciclosporin-associated T cell inactivation could suppress anti-
tumour immunity; alterations in TGFb, il-6 and vascular endothelial 
growth factor synthesis in tumour cells could increase growth, metas-
tasis and angiogenesis; and inhibition of DnA repair could facilitate 
accumulation of mutations. 
in a study following 38 dogs for up to two years of treatment, four 
dogs developed tumours (two malignant mammary tumours [seven- 
and four-year-old dogs], one mast cell tumour [10-year-old dog] and 
one splenic haemangiosarcoma [13-year-old dog]) (radowicz and 
power 2005). Treatment was discontinued in two dogs and main-
tained in two dogs, and all four had a good outcome following surgical 
removal of the tumours. one further dog was euthanased for an oste-
osarcoma that arose 22 months after discontinuation of ciclosporin 
treatment. Two tumours (a benign fibroma and a benign basiloma) 
were seen in a group of eight healthy dogs given 45 mg/kg daily for 
12 months (Donatsch and ryffel 1986). in one clinical trial, histio-
cytomas developed in three of 266 dogs (steffan and others 2005); 
one was surgically removed and two spontaneously regressed without 
recurrence. 
Despite this, there has been no increased prevalence of neoplasia 
reported in any published clinical trials. A single centre, retrospective 
study of 51 dogs receiving ciclosporin from six to 30 months did not 
reveal an increased incidence of neoplasia compared to the general dog 
population (radowicz and power 2005). Moreover, a retrospective 
case control study did not find that ciclosporin treatment for canine 
AD was a significant risk factor for cutaneous lymphoma (santoro 
and others 2007). pharmacovigilance data from 2009 to 2012 showed 
that 160 neoplasms were suspected in ciclosporin-treated dogs, pri-
marily lymphoma/lymphosarcoma, one of the most common neo-
plasms of dogs. The incidence of neoplasia in ciclosporin-treated dogs 
was similar to that of the general population (Dobson and others 
2002). 
Approximately 1 per cent of treated dogs developed a benign lym-
phadenomegaly (steffan and others 2006; novartis Animal Heath, 
unpublished observations). This was self-limiting and reversible, and 
was not associated with malignant transformation. The cause was 
unknown, but did not appear to involve infection or inflammation. 
Conclusions and recommendations
Ciclosporin therapy is not a risk factor for neoplasia at standard doses 
used to manage canine AD. However, because of the potential impact 
on tumour growth and development, ciclosporin is contraindicated in 
the presence of neoplasia as ciclosporin may affect the expression of 
undiagnosed neoplastic conditions. 
Renal failure
in people, renal failure is a frequent severe adverse effect. Acute 
nephrotoxicity is rare with short-term treatment, but dose-depend-
ent and reversible elevations in urea and creatinine associated with 
decreased glomerular filtration are common (Faerber and others 
2001). Vasoconstriction of the afferent artery results from endothe-
lin and thromboxane release and activation of the renin-angiotensin-
aldosterone system (rAAs). long-term treatment can result in dose-
dependent irreversible renal damage, renal failure and hypertension 
(Markham and others 2002).
renal failure associated with ciclosporin treatment in canine AD 
has not been reported in any clinical trials or other publications. There 
are individual cases of increased urea and/or creatinine levels above ref-
erence ranges, but these were either associated with pre-existing renal 
disease or were variable and inconsistent with time. in one unpub-
lished study (H. power, unpublished observations), 15 of 266 dogs had 
elevated creatinine levels after eight or 16 weeks of treatment, but 
only eight of 265 dogs had elevated creatinine at both eight and 16 
weeks. in the same trial, proteinuria was reported in 43 of 154 dogs 
from at least one time point. The frequency of proteinuria did not 
increase during the study, with 23 dogs positive at enrolment but neg-
ative during the trial and 25 dogs negative at enrolment but positive 
during the trial. none of the dogs developed clinical signs consistent 
with renal failure and intervention was unnecessary. in another study 
where 38 dogs had regular blood samples analysed every six months 
for up to two years of treatment there were no consistent abnormali-
ties in haematology or biochemistry parameters associated with ciclo-
sporin (radowicz and power 2005). Most abnormalities were associ-
ated with concurrent conditions. Two dogs had consistently elevated 
alkaline phosphatase levels, but remained healthy. 
Dose dependent increases in renal arterial resistance have been 
reported in experimental dog models (Donatsch and ryffel 1986, 
Carrier and others 1991). However, nephrotoxicity, renal failure and 
hypertension have not been reported in dogs that received up to 14 
mg/kg daily for up to six months or 45 mg/kg ciclosporin daily for up 
to 12 months (Donatsch and ryffel 1986, Vaden and others 1995). 
long-term administration of 20 mg/kg ciclosporin daily did activate 
the rAAs, resulting in chronic sodium retention but not hyperten-
sion in one experimental canine model (Ciresi and others 1992). it is 
possible that the canine rAAs is less responsive to ciclosporin than in 
human or laboratory models. 
Conclusions and recommendations
Ciclosporin-associated nephrotoxicity, renal failure and hyperten-
sion seems to be species specific and has not been recognised in dogs. 
routine monitoring of renal function is not necessary, but care should 
be taken with dogs that have pre-existing or concurrent renal disease. 
Neurological adverse effects
some 10 to 28 per cent of people treated with ciclosporin experience 
a variety of neurological problems, including seizures, paraesthesia, 
cramps, weakness, ataxia, blindness, psychoses and hallucinations. 
Most are mild, but severe neurotoxicity is seen in 5 per cent of patients 
(Bechstein 2000). neurotoxicity in humans is dose dependent and is 
associated with transplant patients, liver failure, hypertension, elevat-
ed cholesterol, decreased magnesium and concurrent glucocorticoid 
therapy (Bechstein 2000). This may result from decreased perfusion 
and ischaemia of the white matter. Acute mild neurotoxicity is usually 
reversible but chronic and/or more severe damage may be permanent. 
neurotoxicity is rare in dogs, with only 0.8 per cent of 759 treated 
dogs reported to have a neurologic problem (Table 1). neurological 
problems were reported at a prevalence of 1 to 4 per cent in two clini-
cal trials (steffan and others 2005, Thelen and others 2006), but were 
not observed in most trials and have a prevalence of less than 1 per 
cent in meta-analyses (steffan and others 2006). seizures were uncom-
mon and no more prevalent than in the general population (Kearsley-
Fleet and others 2013). in most cases seizures were associated with 
underling conditions such as brain tumours and idiopathic epilepsy 
(steffan and others 2005). 
Conclusions and recommendations
neurological complications are rare and not expected with ciclosporin 
use. 
Other adverse effects
lethargy and/or weakness were observed in 1 per cent of 759 treated 
dogs (Table 1) and up to 2.2 per cent of dogs in another meta-analysis 
(steffan and others 2006). pruritus, urticaria, angio-oedema, swollen 
pinnae and cutaneous flushing have been occasionally noted after 
administration of Atopica (olivry and others 2002b, Thelen and oth-
ers 2006, novartis Animal Health, unpublished data). This may rep-
resent an idiosyncratic immune-mediated drug reaction to ciclosporin 
and/or the excipients in the formulation. Clinical signs appeared 
rapidly and completely resolved after withdrawal of the medication. 
preliminary studies in three dogs suggested that ciclosporin may 
increase platelet procoagulant activity (Thomason and others 2012), 
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but no clinically significant effects on coagulation have been reported. 
A variety of other adverse effects, including sebaceous adenitis, crusty 
dermatitis, excessive shedding, coarse coat, alopecia, (pyo)granuloma-
tous nodules, cutaneous cysts, shaking/trembling, hindlimb twitch-
ing, panting, depression, irritability, hyperactivity, increased light sen-
sitivity and reluctance to go outside have been reported in clinical trials 
and other studies (steffan and others 2006, novartis Animal Health, 
unpublished data). However, these affected less than 2 per cent of 
treated dogs, and no clear causal relationship with ciclosporin admin-
istration could be established. in one unpublished meta-analysis, mus-
culoskeletal problems including joint pain and lameness were seen in 
eight of 609 (1.3 per cent) dogs treated with ciclosporin (C. Favrot, 
unpublished observations). 
Vaccination
Ciclosporin may interfere with vaccination efficacy and there is a 
potential for adverse effects from attenuated organisms in immuno-
suppressed animals. in adult cats treated with 24 mg/kg/day of ciclo-
sporin (>3X the therapeutic dose), vaccine titre levels were adequate 
for protection following booster vaccination. in contrast, treated cats 
failed to mount a humoral response to a novel vaccination (FiV). 
However, there are no specific data on lack of efficacy and/or adverse 
effects associated with treatment at standard doses in adult dogs that 
have received a primary course of vaccination. in a small study, 16 
dogs that received either 20 mg/kg daily of ciclosporin or placebo for 
56 days were vaccinated on day 27 with killed rabies and a multi-
valent (distemper, hepatitis, leptospirosis, parainfluenza and modified 
live parvovirus) vaccine. none of the dogs, including the placebo-treat-
ed controls, showed an adequate antibody titre response to the multi-
valent vaccine, whereas all the dogs in both groups responded to the 
killed rabies vaccine. nevertheless, the current summary of product 
Characteristics (revised February 2013) recommends that animals 
should not be given a live or inactivated vaccine during treatment or 
within a two-week interval before or after treatment. 
Conclusions and recommendations
From a public health standpoint, and in accordance with UsA legal 
requirements, killed vaccines (such as the rabies vaccine) produced 
good antibody titres and treatment with ciclosporin is not consid-
ered a contraindication for vaccination. The decision whether or not 
to vaccinate a dog during treatment must be based on a cost-benefit 
analysis, including the consequences of relapse, the feasibility of using 
alternative treatments to cover the treatment gap before and after vac-
cination, and the necessity for vaccination taking into account likely 
exposure and risk. serum antibody titres can be used to help deter-
mine the need for booster vaccination. 
Reproduction
Doses of 30 to 100 mg/kg in laboratory animals are embryo- and feto-
toxic, although no effect was seen at doses of 17 to 30 mg/kg. safety 
has not been studied in or reported in breeding males and breeding, 
pregnant or lactating females at standard doses. However, ciclosporin 
passes the placenta barrier and is excreted via milk, leading to poten-
tial exposure of the fetus and neonates. non-specific effects on repro-
ductive behaviour were reported in seven of 117 dogs in one clinical 
trial in dogs (steffan and others 2003), although this has not been 
noted in other clinical trials where breeding, pregnant or lactating ani-
mals were excluded (Table 1). 
Conclusions and recommendations
in the absence of specific safety studies, ciclosporin is not for use in 
animals intended for breeding, or those that are pregnant or lactating. 
Metabolism and drug interactions
Ciclosporin is mainly metabolised through the liver and, to a lesser 
extent, in the intestine, particularly by cytochrome p450 (CYp3A4). 
Metabolism involves hydroxylation and demethylation to inactive 
metabolites that are mainly excreted in faeces (<10 per cent in urine). 
Ciclosporin is also a p-glycoprotein substrate. substances that affect 
cytochrome p450 and/or p-glycoprotein could therefore alter ciclo-
sporin metabolism. However, the extent of the drug interaction shows 
individual variation, probably associated with variable cytochrome 
p450 and/or p-glycoprotein distribution and activity, as well as fac-
tors such as age and concurrent conditions (Dresser and others 2000, 
robson 2003). 
Competitive inhibitors of cytochrome p450 activity may extend 
the half-life of ciclosporin, increasing ciclosporin concentrations in 
plasma. Ketoconazole administered at 5 to 10 mg/kg can increase 
the blood concentration of ciclosporin in dogs up to five-fold. This 
increase is clinically relevant and ketoconazole has been used to reduce 
the dose of ciclosporin by 38 to 90 per cent (Campana and others 
1996, Dahlinger and others 1998, Mouatt 2002, Guaguère and others 
2004, o’neill and others 2004, palmeiro 2013). However, the interac-
tion can be highly individual, with a 10 to 40 per cent variation in 
tough ciclosporin levels. it can also take two to four weeks to stabilise 
plasma levels after dose adjustment (Mouatt 2002, robson 2003). 
Ciclosporin plasma levels are not predictive of clinical efficacy in 
dogs or cats with AD (Guaguère and others 2004, palmeiro 2013), 
and are not predictive of safety for cats (roberts and others 2012b), as 
plasma concentrations were highly variable. if concomitant treatment 
is necessary, dogs should be carefully monitored and it is recommend-
ed that the initial dose should be halved or the dose interval doubled 
(palmeiro 2013). The most recent study concluded that peak plasma, 
trough plasma and skin concentrations of ciclosporin in six healthy 
beagles were similar after treatment with 5 mg/kg ciclosporin alone or 
2.5 mg/kg ciclosporin combined with 2.5 mg/kg ketoconazole (Gray 
and others 2013). in all studies the effect was variable between indi-
vidual dogs and further individual dose adjustments may be required. 
Fluconazole also significantly increases ciclosporin availability in 
dogs, requiring dose reductions of ciclosporin of 29 per cent to 51 per 
cent (Katayama and others 2008). However, as itraconazole is more 
specific for fungal cytochromes it has less activity on cytochrome 
p450 and ciclosporin metabolism. Effects are variable, but itracona-
zole may increase plasma concentrations two-fold (Campana and 
others 1996, Dahlinger and others 1998, o’neill and others 2004). 
Concomitant treatment with these azole drugs is generally well toler-
ated, but enhanced nephrotoxicity, gingival hyperplasia and insulin 
resistance were reported in people (Campana and others 1996). long-
term safety of these combinations has not been established. 
Erythromycin may increase ciclosporin plasma levels up to two-
fold (Campana and others 1996). There are anecdotal reports of 
decreased ciclosporin concentrations following treatment with clin-
damycin, but a study in six dogs showed no effect and there is no 
evidence of any clinically significant interaction (Campana and others 
1996, Guaguère and others 2004). 
Data from humans suggests that metoclopramide decreases clear-
ance and increases the half-life of ciclosporin, effectively increasing 
availability by 30 per cent (Campana and others 1996), but this has 
not been seen in dogs (radwanski and others 2011). Cimetidine and 
ranitidine may also increase ciclosporin availability (Campana and 
others 1996), although cimetidine did not have any clinical signifi-
cant interaction with ultramicronised emulsified ciclosporin (Atopica) 
in dogs (Guaguère and others 2004). Cimetidine appeared to delay 
absorption of ciclosporin, but did not affect maximal concentration or 
volume of distribution (Daigle and others 2001).
The calcium channel blocker diltiazem also increases plasma 
levels of ciclosporin (robson 2003). A dose of 1 mg/kg every other 
day was reported to facilitate long-term control of pruritus and anal 
furunculosis in two dogs treated with 5 mg/kg ciclosporin every other 
day (robson 2003). Diltiazem has also been shown to prevent renal 
vasoconstriction following ciclosporin administration in dogs (Carrier 
and others 1991) and to reduce hypertension in people (lebwohl and 
others 1998).
liquid or freeze-dried grapefruit juice increases intestinal absorp-
tion of ciclosporin, probably through effects on intestinal mucosa 
cytochrome p450 and p-glycoprotein activity. in eight healthy dogs, 
10 g of powdered whole grapefruit resulted in 29 per cent faster mean 
time to maximum plasma concentrations (Cmax), 54 per cent larger 
area under the curve (AUC) and 38 per cent lower clearance, although 
2 g had no effect (radwanski and others 2011). in another study in 
two healthy crossbred dogs, grapefruit juice doubled the Cmax and 
increased AUC values of ciclosporin by 25 to 27 per cent, although 
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there was little change in the time to Cmax or half-life (Amatori and 
others 2004). 
Drugs that enhance cytochrome p450 and p-glycoprotein activ-
ity, such as phenobarbital and trimethoprim-sulfonamides may lower 
the plasma concentration of ciclosporin (Campana and others 1996). 
similarly, st John’s Wort significantly decreases Cmax and AUC, and 
increases the apparent volume of distribution and clearance in dogs 
(Fukunaga and orito 2012). The effects can last for up to seven days 
after administration. 
Ciclosporin is a substrate and an inhibitor of the MDr1 
p-glycoprotein transporter. Therefore, the co-administration of ciclo-
sporin with p-glycoprotein substrates such as macrocyclic lactones 
(eg, ivermectin and milbemycin) could alter the pharmacokinetics 
of either molecule, potentially resulting in higher blood levels of the 
drugs. in theory, this could decrease the efflux of such drugs from 
blood-brain barrier cells, potentially increasing the risk of Cns toxic-
ity. Ciclosporin may also increase the risk of nephrotoxicity with ami-
noglycosides and trimethoprim (Campana and others 1996). There is 
speculation that ACE inhibitors may also increase nephrotoxicity in 
humans (Campana and others 1996), but there is no evidence for this 
in dogs (Guaguère and others 2004). 
Ciclosporin is highly bound to plasma proteins and lipoproteins. 
However, clinically significant alterations in metabolism through dis-
placement by protein-binding drugs and/or changes in lipoprotein lev-
els have not been reported in dogs (Campana and others 1996).
The interaction between glucocorticoids and ciclosporin is com-
plex and unclear. Variable results, including no changes, increased 
clearance and decreased plasma levels, and decreased clearance with 
increased plasma levels have been seen in humans and animal models 
with concomitant treatment (Campana and others 1996). However, 
no pharmacokinetic interaction between methyl-prednisolone (1 mg/
kg) and ciclosporin (20 mg/kg) was seen in dogs (Guaguère and others 
2004). nevertheless, while short-term two to three week concurrent 
treatment with glucocorticoids and ciclosporin appears well toler-
ated (Dip and others 2013), long-term concomitant therapy should 
be avoided unless clinically justified and treated animals should be 
monitored carefully for signs of immunosuppression.
Conclusions and recommendations
Ciclosporin is well tolerated and concomitant treatment with a wide 
range of drugs (including penicillins, cephalosporins, fluoroquinolo-
nes and nsAiDs) is safe (Campana and others 1996, Guaguère and 
others 2004). However, there are certain specific interactions par-
ticularly involving cytochrome p450 and the MDr1 p-glycoprotein 
transporter. short-term concomitant treatment with drugs that affect 
these pathways resulting in transient elevations in plasma ciclospor-
in concentrations are unlikely to be clinically significant. However, 
long-term concomitant therapy should be clinically justified, carefully 
monitored and where necessary, appropriate dose adjustments should 
be made. 
Monitoring ciclosporin levels
There is marked individual variability in ciclosporin pharmacokinet-
ics. in dogs, for example, trough levels can vary from six- (Griffiths and 
others 1999) to 12-fold (seibel and others 1989b), and peak concentra-
tion can vary from 2.2- (Daigle and others 2001) to 3.4-fold (steffan 
and others 2004) following a constant dose. This may be related to 
individual variation in hepatic cytochrome p-450 3A and intestinal 
p-glycoprotein activity, although obesity may also be a factor through 
preferential distribution to adipose tissue and lipoprotein binding. 
Trough ciclosporin levels correlated with the obesity index in a study 
of humans with psoriasis (Cather and others 2001). 
Monitoring of plasma ciclosporin levels in transplant medicine is 
used to ensure that treatment effectively prevents rejection with mini-
mal adverse effects. This is justified by the relatively small margin 
of safety with higher doses, the consequence of failure and the care 
needed for dose adjustment. However, no correlation between 24 hour 
plasma trough levels and efficacy or safety in canine AD has been 
established (robson 2003, Guaguère and others 2004, palmeiro 2013). 
Values for AUC appear to be better correlated with efficacy and safety 
than 12 or 24 hour tough levels (robson 2003, Guaguère and others 
2004, palmeiro 2013). in addition, there is poor correlation between 
peak or trough plasma concentrations and skin concentration, which 
may be a better predictor of clinical efficacy in canine AD (Gray and 
others 2013). 
Conclusions and recommendations
Monitoring of ciclosporin plasma levels in the treatment of canine 
AD is not justified. However, monitoring could be warranted where 
the margin of safety is lower, for example at higher doses or when 
ciclosporin is combined with a drug known to increase plasma levels 
(eg, ketoconazole). it may also be worth measuring plasma levels in 
dogs that have unexpectedly severe adverse effects or treatment fail-
ures (robson 2003, palmeiro 2013). in these cases, clinicians should 
use individual laboratory standards when evaluating the results as lev-
els from different high performance liquid chromatography (HplC) 
and immunological tests vary markedly (Vaden 1997, robson 2003, 
Guaguère and others 2004, palmeiro 2013).
Conclusions
This review shows that the safety profile for ciclosporin is well char-
acterized. The majority of adverse effects seen in the clinical trials and 
literature are supported by a decade of pV data and the adverse effects 
associated with ciclosporin treatment are described in the approved 
labelling (derived from results of target animal safety, clinical trial, and 
pV data). Gastrointestinal signs, primarily vomiting and diarrhoea, 
are the most often related events accounting for about 50 per cent of 
the adverse effects. Most of the adverse effects occurred with daily 
dosing and tended to resolve with acclimation, dose reduction, or dis-
continuation. As with any drug that modifies the immune system, 
ciclosporin may increase susceptibility to infection and development 
of neoplasia. Various substances are known to competitively inhibit 
or induce the enzymes involved in the metabolism of ciclosporin, in 
particular cytochrome p450. in certain clinically justified cases, an 
adjustment of the dosage of the veterinary medical product may be 
required.
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